Американское общество гирудотерапии

Comparative pharmacology of site directed antithrombin agents. Implication in drug development

Research article published in Thrombosis and haemostasis (1995)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyРазработка лекарственных препаратовCallas DD et al. · Thrombosis and haemostasis, 1995

Abstract

Beside the direct inhibition of thrombin and its regulatory functions, many of the newer antithrombin agents produce several additional effects, unrelated to their anticoagulant actions. Synthetic peptide inhibitors are capable of producing fibrinolytic compromise by virtue of their actions on fibrinolytic enzymes such as t-PA, plasmin, urokinase and protein Ca. In addition, the low molecular weight arginine-containing peptides are also known to produce hemodynamic and hemostatic deficits. The designs of the ongoing clinical trials are largely empirical because of the non-availability of valid pharmacologic and toxicologic data on thrombin inhibitors. In contrast to heparin, none of the thrombin inhibitors produce endogenous release of tissue factor pathway inhibitor (TFPI) in the experimental and clinical settings. These observations suggest that beside the direct inhibition of thrombin, these agents also produce multiple additional effects that can significantly contribute to their pharmacologic and toxicologic profile.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleReview
Indexed MeSH termsAmino Acid SequenceAnimalsAntithrombinsAptamers, NucleotideClinical Trials as TopicDrug DesignDrug Evaluation, PreclinicalFibrinolysisForecastingHemorrhageHirudin TherapyHirudins

Резюме

Comparative pharmacology of site directed antithrombin agents. Implication in drug development.

Почему это важно для гирудотерапии

This review compares the pharmacology of newer antithrombin agents, noting that—beyond direct thrombin inhibition—many produce additional effects such as fibrinolytic compromise (via actions on t-PA, plasmin, urokinase, and protein C) and hemodynamic/hemostatic deficits, and that ongoing clinical-trial designs remain largely empirical. The abstract discusses heparin and synthetic peptide inhibitors but does not mention leeches, hirudin, or hirudotherapy at any point. Consequently, the article's relevance to applied leech therapy is at best indirect and conceptual, offering only general background on antithrombin pharmacology rather than any direct leech-related evidence.

Цитирование

Comparative pharmacology of site directed antithrombin agents. Implication in drug development

Callas DD et al. · Thrombosis and haemostasis, 1995

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.